LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).

Trial Details

NCT ID
NCT07100067
Phase
NA
Sponsor
Nanjing Legend Biotech Co.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • LCAR- F33S cells intravenous infusion
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Tianjin, China|39.14222,117.17667
  • Tianjin, China|39.14222,117.17667
  • Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

  • Subjects voluntarily participate in clinical research.
  • Age ≥18 years old.
  • Eastern Cooperative Oncology Group (ECOG) score 0-2.
  • Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →